News for HH&L Acquisition Co. (HHLA-UN)

PLEASNTON, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. (“DiaCarta”), a novel molecular diagnostic test developer for cancer and infectious...

Abstracts demonstrating XNA technology’s improvements to assay sensitivity across different technology platforms and support for use in companion...

NEW YORK, Oct. 17, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or... | October 17, 2022

Read HH&L Acquisition (NYSE:HHLA) Sees Large Volume Increase at ETF Daily News

DiaCarta, Ltd. , a precision molecular diagnostics company and developer of novel oncology and infectious disease tests, and HH&L Acquisition Co. , a publicly traded special purpose acquisition... | October 14, 2022

Read HH&L Acquisition (NYSE:HHLA) Hits New 52-Week High at $9.89 at ETF Daily News

FWD Group Holdings Limited has announced that Professor Frederick Ma, currently Deputy Chairman and an Independent Non-Executive Director, has been

Read Short Interest in HH&L Acquisition Co. (NYSE:HHLA) Drops By 48.6% at ETF Daily News

Read Contrasting HH&L Acquisition (NYSE:HHLA) & KONE Oyj (OTCMKTS:KNYJY) at ETF Daily News

Read Head to Head Survey: HH&L Acquisition (NYSE:HHLA) and Sangoma Technologies (NASDAQ:SANG) at ETF Daily News

GuruFocus Article or News written by insider and the topic is about: